Press Release

Tarveda Raises $30 Million Series D Financing

February 2, 2017

Boston – February 2, 2017 – Cooley advised Tarveda Therapeutics on its $30 million Series D financing round. New investor Versant Ventures led the round, which also included existing investors New Enterprise Associates, Novo A/S, NanoDimension and Flagship Pioneering.

Tarveda plans to use the funding, in addition to the $38 million raised in its Series C financing in 2016, to advance its novel Pentarin platform.

Tarveda discovers and develops Pentarins, a new class of potent and selective miniaturized drug conjugates with enhanced targeting capabilities for the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized drug conjugate that targets the somatostatin receptor 2 for treatment of patients with neuroendocrine and small cell lung cancers.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.